BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for year-round enhanced education and awareness of these rare diseases and conditions.
Health Technology Insights: Nihon Kohden Launches AlarmSense to Reduce Alarm Fatigue for Clinical Teams
Autoinflammatory diseases refer to problems with the innate immune system’s reactions. Immune cells target the body’s own healthy tissues by mistake, signaling the body to attack them. This can cause intense episodes of inflammation that result in such symptoms as fever, rash, or joint swelling. These diseases also carry the risk of amyloidosis, a potentially fatal buildup of a blood protein in vital organs. Autoinflammatory diseases are typically caused by changes in certain genes. This causes problems with proteins that are important in specific body functions.
Last August was International Autoinflammatory Awareness Month, and BioTek reMEDys has been urging its colleagues, patients, and the population at large to become more aware and help drive education regarding these conditions, year-round.
Health Technology Insights: Brightwood Capital Provides Financing to Support Motor City Dental Partners’ Growth
BioTek reMEDys continues to be vested in the local Rare Disease community. The company’s Chief Pharmacy Officer, Andrew Babb PharmD, CSP, IgCP, was nominated and selected for the inaugural Delaware Rare Disease Advisory Council (RDAC), established by Senate Bill 55 from the 152st General Assembly, and housed within the Lieutenant Governor’s Office. The Council is an advisory body comprised of community advocates, healthcare professionals, scientists, and state leaders that works to educate medical professionals, government agencies, legislators, and the public about rare diseases as an important public health issue and encourage and secure funding for research for the development of new treatments for rare diseases.
“Auto-inflammatory conditions and rare disease at large present such a tremendous challenge for patients, their families, caregivers, and healthcare providers,” said Babb. “Information, support, and guidance can be scarce which only exacerbates the stress these patients feel. At BioTek reMEDys, we are committed to fostering awareness and will continue to advocate for the Rare Disease Community at a local and national level.”
“Because many autoimmune conditions are statistically rare, they can often be misdiagnosed,” said Chai Gadde, CEO and founder of BioTek reMEDys. “As an infusion therapy provider organization focused on the highly specific needs of patients living with rare conditions, we hope to help shine a light on the importance of education about these conditions. Treatments for autoinflammatory diseases are typically very effective and can involve medications that reduce inflammation or suppress the immune system to alleviate symptoms.”
By servicing very specific disease states such as autoinflammatory conditions, BioTek reMEDys’ expert team can maintain its focus on patient care – making sure that dosages and treatments are appropriate.
Health Technology Insights: LucyRx Acquires CerpassRx to Expand Prescription Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
